The inclusion of dynamic drug pricing in cost-effectiveness analysis is important for value assessments of new drugs. The drug price-related provisions of the Inflation Reduction Act make the case ...

To ensure that cost-effectiveness assessments do not perpetuate inequities, alternative approaches are needed that account for the impact of structural factors on different groups and that ...